A basic stomach infection might seem minor, but for millions of children worldwide, it can turn into a life-threatening condition. Severe diarrhea remains one of the top causes of illness and death among young children in many developing nations. In response, scientists have dedicated decades to finding more effective ways to prevent these infections before they happen.
Researchers from the University of Bergen have made significant progress in this effort. They’ve developed a new vaccine technology that has now been licensed to Valneva, a vaccine company, which will continue to advance its development. While this doesn’t mean a vaccine is ready for widespread use just yet, it indicates that experts believe the research shows promising potential.
The new technology targets enterotoxigenic Escherichia coli, or ETEC, a bacteria primarily spread through contaminated food and water. When ETEC enters the body, it releases toxins that cause severe watery diarrhea. While healthy adults typically recover, repeated infections can severely impact infants and young children by leading to dehydration, malnutrition, and delayed growth.
This research was a global collaboration involving the University of Bergen, NORCE, Institut Pasteur, the Indian Institute of Science, Tulane University, and South Dakota State University. The team has been studying ETEC in Bergen since the 1980s, illustrating how lengthy and complex vaccine development can be.
One of the main hurdles was a small toxin called STh. Its tiny size and unique behavior made it difficult to safely include in a vaccine. But instead of abandoning the effort, scientists gradually refined their designs over many years, creating a technology that caught the interest of commercial developers.
Valneva will now invest in the costly process needed to turn lab findings into a usable vaccine. The licensing deal also includes plans to make the vaccine accessible to low- and middle-income countries, where ETEC causes the most harm.
If successful, this vaccine might do more than prevent diarrhea. It could also lead to fewer hospital stays, lower healthcare expenses, better development for children, and reduced antibiotic use—important because growing antibiotic resistance is a global health concern.
However, developing a vaccine takes time, and many promising candidates fail during safety or efficacy testing. Human trials will be necessary to determine if this vaccine offers strong protection. The licensing agreement reflects confidence in the science behind the vaccine but doesn’t guarantee it will be effective.
This progress underscores the importance of sustained scientific partnership and persistence. Instead of reporting clinical results, it highlights a successful shift from academic discovery to commercial development. The main limitation at this stage is the absence of human trial data, but the technology addresses a critical unmet medical need and could significantly improve child health worldwide if future tests are successful.
For those interested in health, recent studies suggest that vitamin D may help reduce autoimmune disease risk, and certain anti-inflammatory drugs might inhibit cancer spread. Other research explores which medications can harm your liver most and how some drugs can enhance the immune system’s ability to fight cancer.
Source: University of Bergen.